Literature DB >> 26486930

Expectant Management of Low-Risk Bladder Cancer.

Zachary L Smith1, Mark S Soloway2.   

Abstract

Patients with one or more low-grade bladder tumors of the urinary bladder will often develop a subsequent tumor but these so called "recurrences" are almost always of similar grade and rarely invade beyond the basement membrane. Therefore, the clinician should try to minimize the morbidity associated with treating these new tumors. Since many of these patients are elderly or have comorbidities, active surveillance is a very reasonable initial approach if these tumors are very small and appear low-grade. Another alternative is fulguration in the outpatient setting using a flexible cystoscope and electrode. The goal is to try to avoid the hospital and performing a formal transurethral resection. This adds potential morbidity, inconvenience, and cost.

Entities:  

Keywords:  Bladder cancer; Low-risk; Management; Tumor

Mesh:

Year:  2015        PMID: 26486930     DOI: 10.1007/s11934-015-0555-1

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  26 in total

Review 1.  Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.

Authors:  M Craig Hall; Sam S Chang; Guido Dalbagni; Raj Som Pruthi; John Derek Seigne; Eila Curlee Skinner; J Stuart Wolf; Paul F Schellhammer
Journal:  J Urol       Date:  2007-12       Impact factor: 7.450

2.  Watchful waiting policy in recurrent Ta G1 bladder tumors.

Authors:  Ofer N Gofrit; Dov Pode; Adi Lazar; Ran Katz; Amos Shapiro
Journal:  Eur Urol       Date:  2006-01-06       Impact factor: 20.096

3.  Trends in stage-specific incidence rates for urothelial carcinoma of the bladder in the United States: 1988 to 2006.

Authors:  Matthew E Nielsen; Angela B Smith; Anne-Marie Meyer; Tzy-Mey Kuo; Seth Tyree; William Y Kim; Matthew I Milowsky; Raj S Pruthi; Robert C Millikan
Journal:  Cancer       Date:  2013-10-10       Impact factor: 6.860

4.  Urothelial susceptibility to neoplastic cellular implantation.

Authors:  T E Weldon; M S Soloway; L Persky
Journal:  Surg Forum       Date:  1974

5.  The actual incidence of bladder perforation following transurethral bladder surgery.

Authors:  M Derya Balbay; Ersin Cimentepe; Ali Unsal; Omer Bayrak; Akif Koç; Ziya Akbulut
Journal:  J Urol       Date:  2005-12       Impact factor: 7.450

Review 6.  Epidemiology and risk factors of urothelial bladder cancer.

Authors:  Maximilian Burger; James W F Catto; Guido Dalbagni; H Barton Grossman; Harry Herr; Pierre Karakiewicz; Wassim Kassouf; Lambertus A Kiemeney; Carlo La Vecchia; Shahrokh Shariat; Yair Lotan
Journal:  Eur Urol       Date:  2012-07-25       Impact factor: 20.096

7.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

Authors:  Richard J Sylvester; Adrian P M van der Meijden; Willem Oosterlinck; J Alfred Witjes; Christian Bouffioux; Louis Denis; Donald W W Newling; Karlheinz Kurth
Journal:  Eur Urol       Date:  2006-01-17       Impact factor: 20.096

8.  Does cystoscopy correlate with the histology of recurrent papillary tumours of the bladder?

Authors:  H W Herr
Journal:  BJU Int       Date:  2001-11       Impact factor: 5.588

9.  Conservative management of low risk superficial bladder tumors.

Authors:  Raj S Pruthi; Nathan Baldwin; Vishal Bhalani; Eric M Wallen
Journal:  J Urol       Date:  2007-11-12       Impact factor: 7.450

10.  Active surveillance of low grade bladder tumors.

Authors:  Ofer N Gofrit; Amos Shapiro
Journal:  Arch Ital Urol Androl       Date:  2008-12
View more
  1 in total

Review 1.  Active surveillance for nonmuscle invasive bladder cancer.

Authors:  Makito Miyake; Kiyohide Fujimoto; Yoshihiko Hirao
Journal:  Investig Clin Urol       Date:  2016-05-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.